Aim Permacol TM collagen paste (Permacol TM paste) is an acellular cross-linked porcine dermal collagen matrix suspension for use in soft-tissue repair. The use of Permacol TM paste in the filling of anorectal fistula tract is a new sphincter-preserving method for fistula repair. The MASER-ATI100 study was a prospective, observational clinical study with the objective to assess the efficacy of Permacol TM collagen paste for anal fistula repair in 100 patients.
Introduction
Treatment options for repair and eradication of anal fistula bear the risk of postoperative faecal incontinence.
Minimally invasive, sphincter-preserving treatments minimize risk of postoperative faecal incontinence, but success rates have been low [1] [2] [3] [4] . Biological infill materials used to fill and close the fistula tract can support and promote tissue healing without damage to the sphincter muscle or surrounding tissue. Such materials include fibrin glue, a fistula plug composed of lyophilized porcine-derived small intestinal submucosa (Biodesign â anal fistula plug; Cook Biotech Incorporated, cells, but their success rates vary widely [5] [6] [7] . Laying open the fistula tract of short intersphincteric fistulae is considered a relatively safe practice, but this method may still pose a small risk of faecal incontinence and wound complications [8] . Thus, the need for alternate treatment options is warranted. The core technology of Permacol TM collagen paste (Medtronic, Mansfield, Massachusetts, USA; henceforth referred to as Permacol TM paste) is also the primary composition for Permacol TM surgical implant (intended for soft tissue repair) and Permacol TM collagen injection (intended for filling and bulking indications). Permacol TM paste is a sterile suspension of acellular crosslinked porcine dermal collagen matrix and saline. It may act as a scaffold to support cellular infiltration, promote tissue vascularization and enable fistula closure without damaging the anal sphincter.. As a paste, Permacol TM is pliable and conforms to the unique shape of the fistula tract, in contrast to other implant materials that may be too liquid or too rigid.
The primary aim of the MASERATI100 clinical study was to assess anal fistula healing at 6 months using Permacol TM paste. The secondary aims were to evaluate fistula healing within 1 year, adverse events, pain, faecal continence, patient satisfaction and quality of life. This manuscript reports the completed 1-year study results including all 100 patients enrolled from 10 investigative sites in Europe.
Method
The MASERATI100 study is a prospective, multicentre, post-market, single-arm observational study on the use of Permacol TM paste in the treatment of anal fistulae in 100 patients. Ten European centres participated. This study received approval from both local and regional Ethics Committees and was conducted according to Good Clinical Practice (GCP) guidelines and with adherence to all European and national regulations.
Study participants
Patients with a clinical diagnosis of cryptoglandular anal fistula were invited to take participate. Inclusion and exclusion criteria have been described in a previous study [9] . Patients with a solitary, primary or recurrent transsphincteric or intersphincteric fistula tract of cryptoglandular origin were eligible. All underwent MRI of the perineum. MRI scans were anonymized and assessed externally by one radiologist. If the operating surgeon deemed that the intra-operative findings met the inclusion criteria, the patient was included in the study and was treated with Permacol TM paste. Patients who gave informed consent but failed to meet the inclusion criteria or refused treatment were considered as screen failures. Patients were reviewed at 1, 3, 6 and 12 months following surgery.
Materials
Permacol TM paste (Medtronic) is contained within a sterile 3-ml syringe with a Luer-Lok connector. The milled collagen matrix suspension was injected into the fistula tract through a flexible cannula sheath (BD Angiocath TM 12GA; Becton Dickinson Medical Systems, Franklin Lakes, New Jersey, USA). Other materials used in the surgical procedure were standard and were provided by the institution at which the patients were treated.
Surgical procedure
No other fistula surgery was to be performed between the MRI and treatment with Permacol TM paste, apart from placement of a draining/loose seton if deemed appropriate. After preoperative eligibility was confirmed, the surgeon proceeded with the surgery using standard surgical procedures based on training provided by the study sponsor. The requirement for bowel preparation was at the surgeon's discretion. Examination under general anaesthesia was performed to confirm the patient's suitability for the study. The internal and external fistula openings were identified. The 'Instructions for Use' for Permacol TM paste were followed, avoiding any dissection in or around the anal sphincter. Any seton was removed and the fistula tract was de-epithelialized with a wire brush or equivalent to remove granulation tissue. The flexible cannula sheath was then inserted into the external opening of the fistula to the internal opening, which was closed by applying finger pressure. Thereafter, the paste was injected to fill the tract completely (Fig. 1) . The tract was judged to be completely filled when paste was visualized at both internal and external openings. The internal opening was closed with a simple resorbable suture. The external opening was also loosely closed with an absorbable suture and this allowed drainage of the fistula, but not extrusion of the paste. A sterile dressing was applied to the wound. Standard postoperative care was provided based on the routines adopted by each investigational site.
Outcome measures
The primary end-point was the rate of fistula healing at 6 months after surgery. Secondary outcome measures were safety, pain, faecal continence, patient satisfaction and quality of life.
Outcome assessments
Patients were assessed for fistula healing and adverse events at 1, 3, 6 and 12 months after surgery by the investigating surgeon. Fistula healing was defined as the absence of any anal symptom or discharge from the treated fistula with a closed external opening confirmed on clinical evaluation. If a patient exited the study after the 3-month follow-up visit with a nonhealed fistula, that patient's fistula was considered to be unhealed at the 6-and 12-month assessments. Incidence and severity of adverse events (AEs) were recorded up to 12 months after surgery. Pain was assessed using a 10-point visual analogue scale (VAS), with the baseline at a screening visit, before and within 60 days of scheduled surgery The VAS was reassessed at each follow-up visit. Faecal continence was assessed before surgery and at each follow-up using the Cleveland Clinical Florida Faecal Incontinence (CCF-FI) questionnaire. At each follow-up, patient satisfaction was measured using a questionnaire and responses were recorded as 'Very Satisfied', 'Satisfied', 'Dissatisfied' or 'Very Dissatisfied'. The EQ-5D Quality of Life (QoL) score was assessed at baseline and at 3, 6 and 12 months after surgery.
Statistical analysis
The sample size of the MASERATI100 clinical study was based on an expected healing rate of 60% and a two-sided 95% CI for a single proportion extended to 10% on either side, with an assumed drop-out rate of 7% at 6 months. The final sample size was determined to be 100 for the evaluable population, and the final analysis included all 100 patients treated. Fistula healing was presented as the number and percentage of patients with a healed fistula at each of the follow-up visits, with a 95% CI. A v 2 test or Fisher's exact test was used to compare percentages of healing. Univariate and multivariate Cox regression analyses were performed to determine if any patient or fistula characteristic impacted fistula healing. The correlation between age and time taken to return to work and normal daily activities was analysed using a Spearman correlation test. CCF-FI scores and patient satisfaction were assessed at completion of the study: either at the last visit before the exit in the case of patients who left the study early; or at the 12-month visit for the patients who completed the study. Differences in pain, CCF-FI score and patient satisfaction from baseline to follow-up visits was compared using the Wilcoxon signed-rank tests or signed tests. The number and percentage of patients with an AE were analysed according to severity and relationship to the paste or the procedure. All tests were two-sided and a value of P < 0.05 was considered statistically significant. All analyses were performed with SAS Version 9.2 (SAS Institute, Inc., Cary, North Carolina, USA).
Results

Participants and procedural characteristics
One hundred out of 143 patients screened were enrolled in the MASERATI100 study between 18 September 2012 and 5 February 2014 with a median follow-up of 50 (1.6-74.4) weeks. The median age of patients was 47.5 (20.0-78.0) yrs. The male to female ratio was 2.3:1 (Table 1) . Fistula tracts ranged from 0.5 to 6.5 cm in length. Most (86%) patients had previously undergone insertion of a loose seton, with median placement of 99 (14-1437) days. Granulation tissue was removed from most (93%) patients (Table 1) . A single unit (≤ 3 ml) of Permacol 96 of 100 patients. Duration of surgery was 21 (10 -55) min. Although most (66%) patients were discharged on the day of the procedure, 29 stayed overnight, and five had a longer admission. The length of stay was influenced by the patient's age, the duration of the procedure and the patient's proximity to the hospital. The median interval from the procedure to return to work and resume normal daily activity was 7 (1-35) days.
A total of 75 patients completed follow-up to 12 months (Fig. 2) . In 25 patients who exited the study early, the fistula failed to heal at the final assessment (n = 18) or the fistula recurred after an initial apparent healing (n = 7). Five patients exited the study at 1 month, 11 at 3 months and eight at 6 months and were considered as unhealed at all subsequent follow-up time points. Only one patient was lost to follow-up after the 3-month visit and at that time the fistula had not healed.
Efficacy of Permacol TM paste
Fistula healing is shown in patients exhibited a recurrence within the 12-month follow-up. Fistula healing at 12 months was associated with no Permacol TM paste extrusion, shorter length of fistula tract (≤ 4 cm) and an intersphincteric fistula (Table 3) . Regression analysis did not confirm that intersphincteric fistulae were more likely to heal (Table 4) . Patients with no evidence of expulsion or leakage of Permacol TM paste (P = 0.002) or those with a shorter fistula tract length (P = 0.030) were more likely to heal (Table 4) . Older patients and patients with a shorter duration of seton implantation (among those with a previous seton) were also more likely to heal (P = 0.004 and 0.040, respectively). Patients with an anal abscess were more than four times more likely to experience treatment failure. Potential risk factors, such as diabetes, obesity, smoking status and previous failed treatments, including fistulotomy and fistulectomy, did not influence the clinical outcome of injection with Permacol TM paste.
Adverse events
Twenty-nine patients experienced at least one AE (Table 5) . AEs experienced by more than two patients included anal abscess, fistula tract infection, postoperative wound infection, procedural pain and proctalgia. Four patients experienced serious adverse events (SAEs), such as new anal fistula, anal abscess, procedural pain and complex regional pain syndrome. Device-related AEs and procedure-related AEs occurred in 16 (16.0%) patients.
Pain, faecal continence, patient satisfaction and QoL
At baseline (within 60 days before surgery), 29 (29.6%) patients were pain free, increasing to 45 (45.9%) at 1 month after surgery. At 12 months after surgery, 66 (89%) patients had only mild pain or no pain at all. Overall, mean patient pain was reduced (P < 0.001), relative to baseline, at all post-procedural follow-up assessments (Fig. 3a) . The mean CCF-FI score was significantly lower (P < 0.05) at the 3-, 6-and 12-month follow-up visits compared with the preoperative baseline assessment (Fig. 3b) , indicating improved faecal continence at these stages. The mean CCF-FI score at all patients' last visit, including the score for those 24 patients who exited the study early, was not significantly different from baseline.
The EQ-5D QoL questionnaire results are reported in Figure 3c . Relative to baseline, significantly fewer subjects reported problems engaging in usual activities or experienced problems with anxiety and depression at the 6-month follow-up. Moreover, significantly fewer subjects had problems with motility and pain/ discomfort at all follow-up visits compared with baseline. Data are expressed as n, n/N (%) or 95% CI. *Includes subjects whose assessment was performed and the final assessment of subjects who exited early from the study. A total of 85 patients completed the satisfaction survey in at least two follow-up visits. Patient satisfaction was assessed at each patient's final visit in order to include patients who exited the study early with unhealed fistula. Regardless of healing status, 73.0% (n = 62) of patients were satisfied or very satisfied, at their last follow-up visit, with the procedure.
Discussion
This study suggests that Permacol TM paste, with healing rates of more than 50%, a low incidence of SAEs and high patient satisfaction, could be useful in managing anal fistula. Fistula closure was fast, with an average time to healing of just over 2 months. In fact, the majority of those who healed after 12 months had done so after 1 month. These final results are largely unchanged from the 54% healing rate of the initial 30 patients reported previously from this study [9] . Pain levels were also satisfactory, with 87.7% of all patients experiencing no, or only mild, pain after 1 month.
The variety of procedures and biological materials available to treat anal fistula have shown unpredictable results (success rates of 16-85%), emphasizing the need for additional clinical data [10] . Too often, studies reporting results of new modalities of treatment for fistula-in-ano have been of limited follow-up duration and have been based on a relatively small number of patients from a single institution. A randomized control trial showed fistula healing rates of 35.3% (n = 51 patients) with fibrin glue and 54.8% (n = 42 patients) with adipose-derived adult stem cells plus fibrin glue [11] , and systemic reviews found healing rates ranging from 16% to 92% for repairs with anal fistula plug [5, 10, 12] . In many instances encouraging initial results have not been reproduced in subsequent studies, and the variation in published outcome generates significant confusion. The MASERATI100 clinical study was designed to minimize any possible bias and produce reliable results, reproducible in everyday clinical settings, by recruiting patients in 10 centres across Europe. Healing was assessed on clinical grounds using the absence of symptoms and the presence of a healed external opening as a surrogate of healing. MRI was not used to measure healing because this was not carried out routinely for this purpose in participating centres and would have added to the cost of the study. Furthermore, there is no evidence of what a healed fistula tract following collagen paste injection would look like on MRI. Before surgery, MRI was used to assess the anatomy and initial complexity of the fistula and to assure that patients met the inclusion criteria.
The MASERATI100 study highlights several novel, previously unknown, factors associated with successful healing with Permacol TM paste. Patients with shorter fistula tracts were more likely to heal, which is in contrast to the collagen fistula plug for which a longer tract has a more favourable outcome, possibly because of a lower displacement risk [13] . Fistula tract anatomy had no impact on healing, with similar rates for intersphincteric and transphincteric tracts. Perhaps the reduced healing observed in the longer tract is related to the resistance of the extrasphincterial tract to heal. If this is correct, then a multistep approach in patients with a long tract involving excision of the extrasphincterial tract and then the use of the Permacol TM paste at a later stage might improve overall healing rates.
Consistent with the interim data, older patients were more likely to heal, a condition possibly attributable to differences in activity levels between younger and older Table 4 Relationship between patient/fistula characteristics and healing rate. patients. However, the physical activity levels of patients after treatment was not assessed in the study.
Those patients who showed no evidence of paste expulsion were also more likely to heal. Treatment failure also occurred even when the implant remained, suggesting that other biological factors may come into play. Undetected sepsis and abscess formation has been previously implicated in treatment failure [14, 15] and, indeed, patients treated with Permacol TM paste were more than four times more likely to fail if they had an anal abscess. Other factors that may contribute to successful healing may be patient populations and comorbidities, bowel-preparation regimens, variations of implant placement technique, suture materials used and closure of the primary opening [5, 16, 17] .
The actual nature of any implant material used for fistula surgery must impact on healing. Fibrin glue, for example, has a fluid consistency that hinders secure fixation of the glue within the tract, preventing proper sealing. The collagen fistula plug has a rigid structure that may lead to a poor fit and extrusion as well as interfering with the healing process by leaving unrecognized Figure 3 Patient pain, faecal continence and quality of life. (a) Pain levels were assessed on a visual analogue scale (VAS) at the baseline visit (before the surgical procedure) and at each follow-up visit. Mean pain was significantly reduced (*P < 0.001) relative to baseline at all follow-up visits [P-values are from sign tests (3-12 months) or Wilcoxon signed-rank tests (1-6 months)]. (b) Faecal continence was assessed at baseline, and at 3, 6 and 12 months, and at all patients' last visit reached. The Cleveland Clinical Florida Faecal Incontinence (CCF-FI) score was a combined assessment of the five types of incontinence (0 = perfect; 20 = complete incontinence). If a patient's CCF-FI assessment was incomplete then the CCF-FI score was not calculated for that visit. Mean CCF-FI faecal continence scores were significantly reduced, relative to baseline, at 3, 6 and 12 months (*P < 0.05 based on Wilcoxon signed-rank tests (at 6 and 12 months) and the sign test (3 months). (c) The EQ-5D Quality of Life questionnaire assessed the percentage of subjects experiencing slight, moderate, severe or extreme problems with particular factors that affect overall quality of life. The questionnaire was completed by 97, 88, 79 and 74 subjects at baseline and 3, 6 and 12 months postoperatively, respectively. *P < 0.05; **P < 0.005, based on McNemar's test for rates comparison between Month X and Baseline. secondary tracts untreated. Surgisis â biomaterial (Cook Biotech) is noncross-linked, possibly leading to bacterial enzymatic degradation in complex environments [18] . In contrast, Permacol TM paste is cross-linked and more readily resists enzymatic degradation while facilitating fibroblast and vascular ingrowth [18] [19] [20] . It is more pliable than a solid implant, allowing better conformation with the unique shape of fistula tracts and minimizing the risk of extrusion.
As expected, injection of Permacol TM paste did not negatively impact faecal continence. In fact CCF-FI scores showed improvement in faecal continence, an observation that may be explained by a reduction of secretion rather than an improvement of sphincter function. While some adverse events were recorded, most were similar to those commonly observed after fistula treatment, such as anal abscess, new anal fistula and procedural pain. The number of patients satisfied or very satisfied with the procedure at the last visit was greater than the number of patients healed, thus even patients in whom the treatment was not successful reported satisfaction. These results might reflect the benign nature of the procedure and therefore even a negative outcome is well accepted. A significant proportion of patients in the study had been previously exposed to more invasive treatments and failures, making injection of Permacol TM paste a much more appealing option, possibly contributing to the very high satisfaction rate following this treatment modality.
The results of this final 1-year analysis suggest that Permacol TM paste is a safe, minimally invasive, sphincterpreserving treatment for anal fistulae that promotes a good healing rate and is well perceived by patients. The lack of a comparative arm is an inherent limitation which we recognize. However, the MASERATI100 study provides a useful assessment of the feasibility and safety of this technique and validates the rationale for future comparative studies between Permacol TM paste and alternative interventions. subsidiary of Medtronic) and BS received honorarium as a speaker for Medtronic.
